Arcutis Biotherapeutics presented clinical data for ZORYVE (roflumilast) across multiple inflammatory skin conditions at major dermatology conferences. The INTEGUMENT-INFANT trial showed the drug was well-tolerated in infants aged 3-24 months with atopic dermatitis, with 34.4% achieving disease clearance at 4 weeks. Additional analyses demonstrated ZORYVE's efficacy in treating psoriasis on special sites including the scalp and genitals, with improvements in sexual function and quality of life. Real-world research highlighted concerns about long-term topical corticosteroid use, including skin thinning and systemic side effects, positioning ZORYVE as a potential alternative therapy.

Arcutis Biotherapeutics announced the grant of 62,500 restricted stock units (RSUs) to six newly hired employees as a material inducement for employment. The RSUs will vest over four years with 25% vesting annually, subject to continued employment. The grants were approved by the Compensation Committee under the company's 2022 Inducement Plan.

Merck announced that its investigational drug tulisokibart met the primary endpoint in a phase IIb study for moderate to severe hidradenitis suppurativa. High-dose and medium-dose regimens demonstrated superiority over placebo, with 72% and 64% of patients achieving HiSCR50 response respectively, compared to 35% for placebo. The drug also showed improvements in quality of life measures. Merck plans to advance tulisokibart into phase III development for HS and is evaluating it across six immune-mediated indications.

The global atopic dermatitis drugs market is projected to grow from USD 15.92 billion in 2025 to USD 33.42 billion by 2035, driven by increased adoption of biologic therapies, JAK inhibitors, and novel treatments. North America leads with 36% market share, while Asia-Pacific shows the fastest growth. Biologics dominate with 42% market share, though high costs and JAK inhibitor safety warnings present challenges.

Arcutis Biotherapeutics announced the grant of 57,000 restricted stock units (RSUs) to 11 newly hired employees as a material inducement for employment. The RSUs will vest over four years with 25% vesting annually, subject to continued employment. The company also announced that management will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026.

Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced it will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026, in New York. Management will participate in a fireside chat on Wednesday, September 16 at 1:50 p.m. ET. The company focuses on developing targeted topicals for chronic inflammatory skin diseases.

Oruka Therapeutics announced the appointment of Todd Edwards as Chief Commercial Officer effective August 24, 2026. Edwards brings over 25 years of commercial leadership experience in immunology and dermatology from previous roles at Arcutis Biotherapeutics, Incyte Corporation, UCB S.A., and AbbVie. The appointment reflects Oruka's commitment to building a commercial organization to advance its pipeline candidates ORKA-001 and ORKA-002 toward commercialization for chronic skin diseases.

Arcutis Biotherapeutics CEO Todd Watanabe sold 4,375 shares for $114,275 on August 3, 2026, to cover tax withholding obligations on vesting restricted stock units. The sale is non-discretionary and does not signal a change in management sentiment. Meanwhile, Arcutis reported strong Q2 2026 results with its flagship product Zoryve generating $129.9 million in revenue (59% growth) and the company achieving profitability with $15 million net income. The company raised full-year guidance to $525-540 million and received FDA approval to expand Zoryve's indication to treat plaque psoriasis in children as young as age 2.

Arcutis Biotherapeutics announced the appointment of Christopher Peetz, CEO of Mirum Pharmaceuticals, to its Board of Directors effective July 15, 2026. Peetz brings extensive biopharmaceutical leadership experience from roles at multiple companies including Onyx Pharmaceuticals and Tobira. The appointment comes as Arcutis continues to expand its ZORYVE (roflumilast) franchise for treating inflammatory skin diseases and evaluates pipeline expansion through strategic acquisitions.

The FDA has approved ZORYVE cream 0.3% for treating plaque psoriasis in children as young as age 2, marking the first once-daily, non-steroidal therapy for this indication. This is Arcutis' seventh FDA approval for ZORYVE in four years. The approval addresses a significant treatment gap for young children with plaque psoriasis, offering a steroid-free option suitable for use anywhere on the body with no duration restrictions.

Arcutis Biotherapeutics director Sue-Jean Lin sold 4,946 shares worth $121,000 on June 15, 2026, under a pre-arranged trading plan. The sale reduced her stake by 15% but she retains over 27,500 shares. The insider transaction appears routine amid strong company performance, with ZORYVE revenue climbing 65% year-over-year to $105.4 million in Q1, and the company narrowing quarterly losses while maintaining positive cash flow.

Antag Therapeutics announced the election of Keith Leonard as Chairman of its Board of Directors. Leonard brings 30 years of biopharmaceutical industry experience, including previous roles as Chairman and CEO of Unity Biotechnology and co-founder/CEO of Kythera Biopharmaceuticals. The appointment comes as Antag prepares to initiate Phase 2a trials of AT7687, its lead GIPR antagonist candidate for obesity treatment.